{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:15:44Z","timestamp":1779380144834,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Research Board","award":["HRA-POR-2015-1116"],"award-info":[{"award-number":["HRA-POR-2015-1116"]}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"crossref","award":["PCI11WAT"],"award-info":[{"award-number":["PCI11WAT"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001631","name":"University College Dublin","doi-asserted-by":"crossref","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001631","name":"University College Dublin","doi-asserted-by":"crossref","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Prostate cancer (PCa) represents a significant healthcare problem. The critical clinical question is the need for a biopsy. Accurate risk stratification of patients before a biopsy can allow for individualised risk stratification thus improving clinical decision making. This study aims to build a risk calculator to inform the need for a prostate biopsy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Using the clinical information of 4801 patients an Irish Prostate Cancer Risk Calculator (IPRC) for diagnosis of PCa and high grade (Gleason \u22657) was created using a binary regression model including age, digital rectal examination, family history of PCa, negative prior biopsy and Prostate-specific antigen (PSA) level as risk factors. The discrimination ability of the risk calculator is internally validated using cross validation to reduce overfitting, and its performance compared with PSA and the American risk calculator (PCPT), Prostate Biopsy Collaborative Group (PBCG) and European risk calculator (ERSPC) using various performance outcome summaries. In a subgroup of 2970 patients, prostate volume was included. Separate risk calculators including the prostate volume (IPRCv) for the diagnosis of PCa (and high-grade PCa) was created.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>IPRC area under the curve (AUC) for the prediction of PCa and high-grade PCa was 0.6741 (95% CI, 0.6591 to 0.6890) and 0.7214 (95% CI, 0.7018 to 0.7409) respectively. This significantly outperforms the predictive ability of cancer detection for PSA (0.5948), PCPT (0.6304), PBCG (0.6528) and ERSPC (0.6502) risk calculators; and also, for detecting high-grade cancer for PSA (0.6623) and PCPT (0.6804) but there was no significant improvement for PBCG (0.7185) and ERSPC (0.7140). The inclusion of prostate volume into the risk calculator significantly improved the AUC for cancer detection (AUC\u2009=\u20090.7298; 95% CI, 0.7119 to 0.7478), but not for high-grade cancer (AUC\u2009=\u20090.7256; 95% CI, 0.7017 to 0.7495). The risk calculator also demonstrated an increased net benefit on decision curve analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The risk calculator developed has advantages over prior risk stratification of prostate cancer patients before the biopsy. It will reduce the number of men requiring a biopsy and their exposure to its side effects. The interactive tools developed are beneficial to translate the risk calculator into practice and allows for clarity in the clinical recommendations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12911-020-01174-2","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T06:14:56Z","timestamp":1593756896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-8261","authenticated-orcid":false,"given":"Amirhossein","family":"Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Maweni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keefe","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara J.","family":"Lundon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran J.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett C.","family":"Durkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Brendan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. William","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"1174_CR1","unstructured":"National Cancer Registry (2014) Cancer in Ireland 1994\u20132011: Annual report of the National Cancer Registry 2014. http:\/\/www.ncri.ie\/sites\/ncri\/files\/pubs\/annual report 2014.pdf. Accessed 2 Jul 2014."},{"issue":"5","key":"1174_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359\u201386.","journal-title":"Int J Cancer"},{"key":"1174_CR3","unstructured":"National Cancer Registry (2010) Cancer Trends. No. 3. Recent trends in prostate cancer."},{"key":"1174_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jpeds.2009.02.048","volume":"155","author":"AV Kulkarni","year":"2009","unstructured":"Kulkarni AV, Drake JM, Mallucci CL, Sgouros S, Roth J, Constantini S. Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus. J Pediatr. 2009;155:254\u20139.e1.","journal-title":"J Pediatr"},{"key":"1174_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1161\/01.CIR.91.6.1659","volume":"91","author":"KL Lee","year":"1995","unstructured":"Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I investigators. Circulation. 1995;91:1659\u201368.","journal-title":"Circulation"},{"key":"1174_CR6","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1200\/JCO.2011.36.1329","volume":"29","author":"AJ Vickers","year":"2011","unstructured":"Vickers AJ. Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol. 2011;29:2951\u20132.","journal-title":"J Clin Oncol"},{"key":"1174_CR7","doi-asserted-by":"publisher","unstructured":"Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2014. https:\/\/doi.org\/10.1093\/annonc\/mdu525.","DOI":"10.1093\/annonc\/mdu525"},{"key":"1174_CR8","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83:1362\u20137.","journal-title":"Urology"},{"issue":"2","key":"1174_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018;74(2):197\u2013203.","journal-title":"Eur Urol"},{"key":"1174_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","volume":"61","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61:577\u201383.","journal-title":"Eur Urol"},{"issue":"2016","key":"1174_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bju.13437","volume":"118","author":"RW Foley","year":"2016","unstructured":"Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, et al. European randomised study of screening for prostate Cancer (ERSPC) risk calculators significantly outperform the prostate Cancer prevention trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016;118, no 5(2016):706\u201313.","journal-title":"BJU Int"},{"key":"1174_CR12","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1464-410X.2008.07940.x","volume":"102","author":"RCN van den Bergh","year":"2008","unstructured":"van den Bergh RCN, Roobol MJ, Wolters T, van Leeuwen PJ, Schr\u00f6der FH. The prostate Cancer prevention trial and European randomized study of screening for prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int. 2008;102:1068\u201373.","journal-title":"BJU Int"},{"key":"1174_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","volume":"29","author":"JI Epstein","year":"2005","unstructured":"Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228\u201342.","journal-title":"Am J Surg Pathol"},{"key":"1174_CR14","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2014","unstructured":"Core Team R. R: a language and environment for statistical computing. Austria: Foundation for Statistical Computing; 2014."},{"key":"1174_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1472-6947-13-126","volume":"13","author":"S Boyce","year":"2013","unstructured":"Boyce S, Fan Y, Watson RW, Murphy TB. Evaluation of prediction models for the staging of prostate cancer. BMC Med Inform Decis Mak. 2013;13:126.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1174_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"1174_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"E Steyerberg","year":"2009","unstructured":"Steyerberg E. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2009."},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26:565\u201374.","journal-title":"Med Decis Mak"},{"key":"1174_CR19","unstructured":"Threshold selection application for IPRC model (cancer diagnosis). https:\/\/optiprostate.shinyapps.io\/IPRC_threshold. Accessed 28 Jan 2019."},{"key":"1174_CR20","unstructured":"Irish Prostate Cancer Risk Calculator. https:\/\/optiprostate.shinyapps.io\/IPRC. Accessed 3 Feb 2019."},{"key":"1174_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2011.04.029","volume":"60","author":"CT Nguyen","year":"2011","unstructured":"Nguyen CT, Kattan MW. How to tell if a new marker improves prediction. Eur Urol. 2011;60:226\u20138 discussion 228\u201330.","journal-title":"Eur Urol"},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/j.1464-410X.2011.10611.x","volume":"109","author":"HA van Vugt","year":"2012","unstructured":"van Vugt HA, Roobol MJ, Busstra M, Kil P, Oomens EH, de Jong IJ, et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int. 2012;109:1480\u20138.","journal-title":"BJU Int"},{"key":"1174_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00345-011-0804-y","volume":"30","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, Schr\u00f6der FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al. Importance of prostate volume in the European randomised study of screening for prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol. 2012;30:149\u201355.","journal-title":"World J Urol"},{"key":"1174_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2013.05.059","volume":"64","author":"MM Siddiqui","year":"2013","unstructured":"Siddiqui MM, Rais-Bahrami S, Truong H, Jones JS, Kattan MW, Klein EA, et al. Magnetic resonance imaging\/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64:713\u20139.","journal-title":"Eur Urol"},{"key":"1174_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/bju.13143","volume":"117","author":"RW Foley","year":"2015","unstructured":"Foley RW, Gorman L, Sharifi N, Murphy K, Moore H, Tuzova AV, et al. Improving multivariable prostate Cancer risk assessment using the prostate health index. BJU Int. 2015;117:409\u201317.","journal-title":"BJU Int"},{"key":"1174_CR26","doi-asserted-by":"crossref","unstructured":"Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, et al. Predicting high-grade Cancer at ten-Core prostate biopsy using four Kallikrein markers measured in blood in the ProtecT study. JNCI. 2015;107(7).","DOI":"10.1093\/jnci\/djv095"},{"key":"1174_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.juro.2014.09.018","volume":"193","author":"S Grill","year":"2015","unstructured":"Grill S, Fallah M, Leach RJ, Thompson IM, Freedland S, Hemminki K, et al. Incorporation of detailed family history from the Swedish family Cancer database into the PCPT risk calculator. J Urol. 2015;193:460\u20135.","journal-title":"J Urol"},{"key":"1174_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.eururo.2007.12.017","volume":"53","author":"S Roemeling","year":"2008","unstructured":"Roemeling S, Schr\u00f6der FH. Words of wisdom. Re: needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. Eur Urol. 2008;53:663\u20134.","journal-title":"Eur Urol"},{"key":"1174_CR29","doi-asserted-by":"publisher","unstructured":"Strobl AN, Thompson IM, Vickers AJ, Ankerst DP. The next generation of clinical decision-making tools: development of a real-time prediction tool for outcome of prostate biopsy in response to a continuously evolving prostate Cancer landscape. J Urol. 2015. https:\/\/doi.org\/10.1016\/j.juro.2015.01.092.","DOI":"10.1016\/j.juro.2015.01.092"},{"key":"1174_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1464-410X.2011.10923.x","volume":"110","author":"JC Forde","year":"2012","unstructured":"Forde JC, Marignol L, Blake O, McDermott T, Grainger R, Crowley VE, et al. Standardization of assay methods reduces variability of total PSA measurements: an Irish study. BJU Int. 2012;110:644\u201350.","journal-title":"BJU Int"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-01174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-020-01174-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-01174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T23:33:23Z","timestamp":1625268803000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-020-01174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1186\/s12911-020-01174-2","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was awarded from respective hospitals (Beaumont Hospital Ethics committee \u2013 Ref: \/20, Cork University Hospital Clinical Research Ethics Committee \u2013 Ref: ECM4 07\/02\/17, Galway University Hospital Clinical Research Ethics Committee - Ref: CA1221, Mater Misericordia University Hospital Ethics Committee \u2013 Ref: \/378\/1714, St Vincent University Hospital Ethics Committee \u2013 Ref (none given they use title of study), St James Hospital Ethical Committee \u2013 Ref: 2017\u201301, Waterford University Hospital Ethics Committee \u2013 Ref: none given they use title of study) to undertake this study and have access to the anonymised patient data. IRB approval was granted from each of the hospital sites that hosted the rapid access clinics. Anonymous data was obtained negating the need for individual patient signed consent as approved by the IRBs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}